UA139006U - METHOD FOR PREDICTING THE DEVELOPMENT OF OSTEOARTHRITIS - Google Patents

Abstract

The method of predicting the development of osteoarthritis includes clinical examination, radiography. Additionally, in the patient's serum determine the polymorphism of methylenetetrahydrofolate reductase (MTHFR C677T), nitric oxide synthase (eNOS T786C), the content of oxyproline, osteocalcin, transforming growth factor beta 1 (TGF-b1). With a homozygous carrier of 677-TT, 786-CC and levels of oxyproline> 15 μmol / l, osteocalcin <21 ng / ml, TGF-b1 <14 ng / ml predict the development of osteoarthritis.

Description

A useful model, namely a method of predicting the development of osteoarthritis, belongs to medicine, in particular to orthopedics and rheumatology. It is prescribed and can be used in the diagnosis of the development of osteoarthritis in the early stages.

Methods of predicting the development of osteoarthritis are known. These include radiography, examination of biopsies of the synovial membrane, synovial fluid, and cartilage biopsies (Okorokov

A.N. Diagnosis of diseases of internal organs. M, 2001. - Vol. 2. - P. 186-196). The disadvantage of these methods is the lack of the possibility of predicting the dynamics of the process in the early subclinical stages, preventing its development and possible complications due to the internal characteristics of the body.

The basis of a useful model is the task of developing a method that would allow predicting the development of osteoarthritis in the early stages.

The task is solved by the fact that, in addition to clinical examination and radiography, polymorphism of methylenetetrahydrofolate reductase genes (MTNEK) is determined in the patient's blood serum

Sb677T), nitric oxide synthase (eMmoOo5 T786C), content of oxyproline, osteocalcin, transforming growth factor beta 1 (TGF-P1). With homozygous carrier 677-TT, 786-SS, levels of oxyproline "15 μmol/l, osteocalcin "21 ng/ml, TFR-D1 "14 ng/ml predict the development of osteoarthritis.

Application of the method

During hospitalization, the patient is examined, X-rays are taken, the polymorphism of MTNEK C677T, emMmo5 1786C genes is determined by the immunoenzymatic method: the content of oxyproline, osteocalcin, TGF-R1. With homozygous carrier 677-TT, 786-SS, levels of oxyproline 215 μmol/l, osteocalcin "21 ng/ml, TFR-D1 "14 ng/ml predict the development of osteoarthritis.

A specific example of using the method.

Patient Sh., 69 years old, was admitted to the clinic due to pain syndrome in the right hip joint. Examined, X-ray taken. No signs of osteoarthritis were found. Polymorphisms of MTNEK C677T and emo5 T786C genes were determined in blood serum. The content of oxyproline, osteocalcin, TGF-D1 was determined by immunoenzymatic method. Homozygous carriers of 677-TT and 786-SS were established, oxyproline levels - 33 μmol/l, osteocalcin - 14 ng/ml, TGF-D1 - 8.5 ng/ml. The development of osteoarthritis was diagnosed. After 12 months, X-rays revealed

From the phenomenon of osteoarthritis.

Thus, the proposed method is informative and allows diagnosing the development of osteoarthritis at an early stage.

Claims (1)

USEFUL MODEL FORMULA The method of predicting the development of osteoarthritis, which includes a clinical examination, radiography, which is distinguished by the fact that, in addition, in the patient's blood serum, the polymorphism of the genes methylenetetrahydrofolate reductase (MTNEK С677Т), nitric oxide synthase (6еМО5 T786С), the content of oxyproline, osteocalcin, transforming growth factor beta 1 ( TFR-DRI), and with homozygous carriers of 677-TT, 786-SS and levels of oxyproline 215 μmol/l, osteocalcin "21 ng/ml, TFR-D1 "14 ng/ml predict the development of osteoarthritis.